Two years after AbbVie’s loss of market exclusivity for Humira, those “How it Started and How it’s Going” memes are looking better each quarter for the Illinois drugmaker. On Friday, when AbbVie ...
AbbVie’s lost exclusivity for Humira is offset by immunology and neurology sales, diversified by its emerging oncology ...
ABBV has rebounded after Humira patent cliff, with Skyrizi and Rinvoq driving growth. Rising estimates and a pipeline set to ...
AbbVie's Q4 and full-year 2024 earnings surpassed expectations, driven by strong performance from Skyrizi and Rinvoq, despite Humira's revenue decline due to patent expirations. Management's guidance ...
AbbVie ABBV is a dominant player in the immunology space, powered by three blockbuster drugs — Skyrizi, Rinvoq and Humira — which together account for nearly half of its top line. Although the company ...
Zacks Investment Research on MSN
AbbVie down 3% in a month: Why holding the stock still makes sense
AbbVie ABBV stock has declined 3.2% in a month. Shares of this large drugmaker dipped recently after it denied takeover talks ...
Oct 25 (Reuters) - AbbVie Inc on Friday reported stronger-than-expected results for the third quarter, as booming sales of its Humira arthritis treatment and Synthroid thyroid replacement drug more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback